Full text is available at the source.
Abstract
Mesenchymal stem cell-derived exosomes (MSC-Exos) combined with CRISPR-Cas9 have potential therapeutic applications for immune-mediated diseases.
- Engineering MSC-Exos as delivery vehicles for CRISPR-Cas9 involves specific methods for loading cargo and modifying surfaces to target immune cells.
- The therapeutic effects of these engineered platforms are linked to their ability to effectively deliver gene-editing tools.
- Challenges remain in scaling manufacturing processes, ensuring safety, and navigating regulatory hurdles for clinical use.
- Key considerations include optimizing vehicle design, enhancing cargo packaging efficiency, and overcoming biological barriers.
- Next-generation gene editors and responsive biomaterials may offer new directions for improving these nanoplatforms.
Simplified